Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Chief Marketing Officer Todd Berard had 470 shares of common stock withheld by the company on the RSU vesting date to cover tax obligations. This was a tax-withholding disposition, not an open-market sale. After this withholding, he directly holds 162,942 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a small share disposition related to taxes, not an open-market trade. On the transaction date, 420 shares of Common Stock were withheld by the company at a price of $26.04 per share to cover tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, Werner held a remaining direct position of 47,831 Common Stock shares.
BioLife Solutions President and CEO Roderick De Greef reported a routine tax-related share withholding. The company withheld 2,775 shares of common stock to satisfy his tax obligations when restricted stock units were released. After this non-market transaction, he directly holds 730,971 shares of BioLife Solutions common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 937 shares of Common Stock to cover his tax obligations at a value of $26.04 per share. After this withholding, Wichterman directly holds 214,093 shares of BioLife Solutions common stock, indicating that the event reflects compensation-related tax settlement rather than an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small share disposition tied to taxes rather than a market trade. On the release of restricted stock units, 564 shares of common stock were withheld by the company at $26.04 per share to satisfy his tax obligations. After this automatic tax-withholding event, he directly holds 388,976 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the reported date, 1,026 shares of common stock were withheld by the company to satisfy his tax withholding obligations arising from the release of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, Wichterman directly holds 215,030 shares of BioLife Solutions common stock, indicating he retains a substantial equity position. This filing reflects a compensation-related, non-discretionary transaction tied to vesting, not an active decision to buy or sell shares on the market.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported a routine tax-related share disposition. On the release of restricted stock units, 356 shares of Common Stock were withheld by the company to cover his tax withholding obligations. Following this, he directly holds 163,412 shares, so his overall stake remains largely unchanged and the transaction does not represent an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small, routine share disposition related to taxes. On June 8, 2026, 627 shares of common stock were withheld at $26.10 per share to satisfy tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, he directly held 389,540 shares of common stock.
BioLife Solutions Inc. ownership update: Casdin Capital, LLC and related entities report shared beneficial ownership of 4,757,165 shares of Common Stock, representing 9.7% of the class as reported on 06/04/2026. The reported shares are held by advisory clients, including Casdin Partners Master Fund, L.P., and the filing disclaims direct sole voting or dispositive power.
BioLife Solutions, Inc. furnished an investor presentation outlining its strategy and recent financial performance for cell-based therapy tools. The company reported pro forma 2025 revenue of $96.2M, up 29% from 2024, with a 65% gross margin and 26% adjusted EBITDA margin.
Q1 2026 revenue was $27.5M with adjusted EBITDA of $6.2M, a 22% margin. Management highlights leadership in biopreservation media, growing adoption across more than 950 active clinical trials and multiple approved therapies, and targets 17–20% revenue growth and positive GAAP net income for full-year 2026.